|Dr. Nassim Usman||Pres, CEO & Director||726.57k||N/A||1960|
|Mr. Fletcher Payne||Chief Financial Officer||468.25k||N/A||1963|
|Dr. Howard Levy||Chief Medical Officer||540.38k||N/A||1954|
|Dr. Charles S. Craik||Co-Founder & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Andrew Hetherington M.B.A.||Sr. VP of Technical Operations||N/A||N/A||N/A|
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company was founded in 2002 and is headquartered in South San Francisco, California.
Catalyst Biosciences, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 7. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 9.